These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 38467235)
1. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors. Hussain S; Mursal M; Verma G; Hasan SM; Khan MF Eur J Pharmacol; 2024 May; 970():176484. PubMed ID: 38467235 [TBL] [Abstract][Full Text] [Related]
2. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Roskoski R Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356 [TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Roskoski R Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Funakoshi T; Latif A; Galsky MD Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273 [TBL] [Abstract][Full Text] [Related]
5. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Galvani E; Alfieri R; Giovannetti E; Cavazzoni A; La Monica S; Galetti M; Fumarola C; Bonelli M; Mor M; Tiseo M; Peters GJ; Petronini PG; Ardizzoni A Curr Pharm Des; 2013; 19(5):818-32. PubMed ID: 22973953 [TBL] [Abstract][Full Text] [Related]
7. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. Zhao Y; Wang H; He C J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758 [TBL] [Abstract][Full Text] [Related]
8. Properties of FDA-approved small molecule protein kinase inhibitors. Roskoski R Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063 [TBL] [Abstract][Full Text] [Related]
9. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
10. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402 [TBL] [Abstract][Full Text] [Related]
11. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281 [TBL] [Abstract][Full Text] [Related]
17. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. Socinski MA; Villaruz LC; Ross J Oncologist; 2017 Jan; 22(1):3-11. PubMed ID: 27821794 [TBL] [Abstract][Full Text] [Related]
18. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Roskoski R Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477 [TBL] [Abstract][Full Text] [Related]
19. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]